Beam Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Beam Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201.
CEOJohn Evans
CEOJohn Evans
Employees483
Employees483
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2017
Founded2017
Employees483
Employees483
BEAM Key Statistics
Market cap2.75B
Market cap2.75B
Price-Earnings ratio-6.11
Price-Earnings ratio-6.11
Dividend yield—
Dividend yield—
Average volume2.29M
Average volume2.29M
High today$29.15
High today$29.15
Low today$27.00
Low today$27.00
Open price$28.73
Open price$28.73
Volume2.14M
Volume2.14M
52 Week high$35.25
52 Week high$35.25
52 Week low$13.53
52 Week low$13.53
Stock Snapshot
The current Beam Therapeutics(BEAM) stock price is $27.98, with a market capitalization of 2.75B. The stock trades at a price-to-earnings (P/E) ratio of -6.11.
On 2025-12-08, Beam Therapeutics(BEAM) stock traded between a low of $27.00 and a high of $29.15. Shares are currently priced at $27.98, which is +3.6% above the low and -4.0% below the high.
The Beam Therapeutics(BEAM)'s current trading volume is 2.14M, compared to an average daily volume of 2.29M.
During the past year, Beam Therapeutics(BEAM) stock moved between $13.53 at its lowest and $35.25 at its peak.
During the past year, Beam Therapeutics(BEAM) stock moved between $13.53 at its lowest and $35.25 at its peak.
Analyst ratings
88%
of 17 ratingsBuy
88.2%
Hold
11.8%
Sell
0%
People also own
Based on the portfolios of people who own BEAM. This list is generated using Robinhood data, and it’s not a recommendation.